Private Advisory Group LLC Sells 4,340 Shares of Johnson & Johnson $JNJ

Private Advisory Group LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 9.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,472 shares of the company’s stock after selling 4,340 shares during the quarter. Private Advisory Group LLC’s holdings in Johnson & Johnson were worth $10,450,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Jupiter Topco LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth approximately $1,967,399,000. Corient Private Wealth LP raised its stake in Johnson & Johnson by 127.3% in the 2nd quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company’s stock valued at $1,539,292,000 after purchasing an additional 3,393,981 shares during the last quarter. Wellington Management Group LLP raised its stake in Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares during the last quarter. Amundi lifted its holdings in Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Finally, SEB Asset Management AB purchased a new position in Johnson & Johnson in the 1st quarter valued at $314,468,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.2%

Shares of NYSE:JNJ opened at $283.69 on Friday. The company has a market capitalization of $682.93 billion, a price-to-earnings ratio of 42.98, a PEG ratio of 2.77 and a beta of 0.22. Johnson & Johnson has a 12-month low of $193.45 and a 12-month high of $286.08. The business has a 50-day moving average price of $266.83 and a 200 day moving average price of $249.54. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter last year, the company posted $2.80 EPS. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

Trending Headlines about Johnson & Johnson

Investors following JNJ have been watching these headlines:

• Positive Sentiment: The company is backing Francis Medical as it advances its Vanquish water-vapor therapy device for prostate cancer through the FDA premarket approval process. J&J also led a $100 million funding round for Delix Therapeutics, supporting development of psychedelic-inspired depression treatments. The deals broaden its potential reach in cancer care and psychiatry, though both carry development and regulatory risk. J&J leads Francis Medical investment to fund prostate cancer device Johnson & Johnson backs new cancer device and leads $100 million depression bet
• Negative Sentiment: A Massachusetts jury awarded $3.3 million to the family of a woman who developed mesothelioma after using J&J talc-based baby powder. The award adds to ongoing talc-related litigation exposure. Massachusetts woman’s family awarded $3.3 million against Johnson & Johnson
• Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of J&J investors. The announcement does not establish wrongdoing or the outcome of any claims, but adds another legal headline for investors to monitor. Pomerantz law firm investigates claims on behalf of J&J investors

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Johnson Rice lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 29th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. HSBC increased their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Finally, Argus set a $300.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.